



Assessing physical function and activity for survivors of a critical illness: A review of instruments

Doug Elliott PhD, RN^{a,*},
Linda Denehy PhD, BAppSc (Physio)^b,
Sue Berney PhD BPhysio^c,
Jennifer A. Alison PhD MSc, Dip Phty^d

^a Faculty of Nursing, Midwifery and Health, University of Technology, Sydney, NSW, Australia

^b Melbourne School of Health Sciences, The University of Melbourne, Parkville, Vic, Australia

^c Austin Hospital, Heidelberg, Vic, Australia

^d Discipline of Physiotherapy, Faculty of Health Sciences, The University of Sydney, NSW, Australia

Received 8 March 2011; received in revised form 9 May 2011; accepted 31 May 2011

KEYWORDS

Physical function;
Health-related quality
of life;
Measuring instruments;
Clinical utility

Summary

Background: Functional outcomes and health-related quality of life are important measures for survivors of a critical illness. Studies have demonstrated debilitating physical effects for a significant proportion of surviving patients, particularly those with intensive care unit-acquired weakness. Contemporary practice changes include a focus on the continuum of critical illness, with less sedation and more physical activity including mobility while in ICU, and post-ICU and post-hospitalisation activities to support optimal recovery. How to best assess the physical function of patients at different phases of their recovery and rehabilitation is therefore important.

Purpose: This narrative review paper examined observational and functional assessment instruments used for assessing patients across the in-ICU, post-ICU and post-hospital continuum of critical illness.

Methods: Relevant papers were identified from a search of bibliographic databases and a review of the reference list of selected articles. The clinimetric properties of physical function and HRQOL measures and their relevance and utility in ICU were reported in narrative format.

Findings: The review highlighted many different instruments used to measure function in survivors of ICU including muscle strength testing, functional tests and walk tests, and patient centred outcomes such as health related quality of life. In general, the sensitivity and validity of these instruments for use with survivors of a critical illness has not yet been established.

* Corresponding author. Tel.: +61 2 9514 4832; fax: +61 2 9514 4835.
E-mail address: Doug.Elliott@uts.edu.au (D. Elliott).

Conclusion: Based on findings from the review, screening of patients using reliable and valid instruments for ICU patients is recommended to inform both practice and future studies of interventions aimed at improving recovery and rehabilitation.

© 2011 Australian College of Critical Care Nurses Ltd. Published by Elsevier Australia (a division of Reed International Books Australia Pty Ltd). All rights reserved.

Introduction

Examining functional outcomes and health-related quality of life (HRQOL) for survivors of a critical illness is a contemporary area of interest for clinicians and researchers as mortality rates stabilise. With survival rates of 89% at hospital discharge¹ but delayed functional recovery evident from reviews of observational studies internationally,^{2–4} practice initiatives to improve the recovery trajectory for a patient's 'continuum of critical illness'⁵ are now being explored. This current view of an episode of critical illness as a continuum, commences with acute clinical deterioration, a period of treatment and care in the intensive care unit (ICU), and continues after ICU and hospital discharge until the patient's risk of late sequelae has returned to the baseline risk of a similar individual who has not incurred a critical illness.⁵

Delays in physical recovery have prompted a focus on rehabilitation strategies. Current evidence suggests that intensive care unit-acquired weakness (ICU-AW) syndrome results from a combination of the presenting illness (commonly sepsis), treatments and bed rest.^{6,7} The term ICU-AW was developed to encompass critical illness myopathy (CIM), polyneuropathy (CIP) and neuromyopathy (CINM), and reflects muscle wasting and functional weakness in patients with a critical illness who have no other plausible aetiology.⁸ With changes in practice to less sedation and more physical activity including mobility while in ICU,⁹ and a focus on the continuum of critical illness to post-ICU and post-hospitalisation support for optimal recovery, there is a need to explore how to best assess the physical function and HRQOL of these patients at different phases of their recovery and rehabilitation.

Search methods

This narrative review examined the current evidence base for assessing physical function, mobility, health-related quality of life (HRQOL) and utility measures in patients with a critical illness, focusing on the common instruments used during in-ICU, post-ICU and post-hospital testing. Specific

functional outcome measures used in ICU research were retrieved using the bibliographic databases PubMed and CINAHL, with additional sources identified from the reference list of selected articles. Search results were filtered for English-language. The clinimetric properties of physical function and HRQOL measures and their relevance and utility in ICU were reported in narrative format.

Findings

Search results are discussed using the following themes: functional tests, walk tests, strength tests, and HRQOL. Utility measures are also discussed within the scope of this topic.

Functional tests

Tests of functional status assess Activities of Daily Living (ADL), either as a self-report or during observation. Assessment of both upper and lower limb function provide an advantage over walk tests if the outcome measurement relates to specific functional tasks requiring upper limb use. Tests that assess functional status and are relevant for patients across their continuum of critical illness⁵ include the Barthel Index (BI),¹⁰ Functional Independence Measure (FIM),¹¹ the Physical Function in ICU Test (PFIT),¹² and Glittre ADL Test,¹³ (see [Table 1](#)). The FIM was identified as providing a better measure of disability in medical rehabilitation cohorts when compared to the BI and other instruments.¹⁴ The Glittre ADL Test¹³ has been used in assessing patients with chronic obstructive pulmonary disease (COPD) and may have utility in assessing recovery and function in post-ICU patients, but this has not yet been evaluated in a research setting.

Only the PFIT was developed specifically for an ICU patient cohort; others were developed for other clinical specialities, primarily medical rehabilitation and aged care, however the BI and FIM have been used to assess survivors of a critical illness.¹⁵ The FIM has been modified in more recent ICU research,¹⁶ where only the specific aspects of function relevant to patients in ICU were examined

Table 1 Summary of common functional and walk tests applicable for assessing survivors of a critical illness.

Instrument	Description	Interpretation	Comments
<i>Functional tests</i>			
Physical Function ICU Test (PFIT) ¹²	4 domains once patient able to sit out of bed: sit to stand, marching on the spot, shoulder flexion, muscle strength ^e	No total score calculated; enables prescription of activities based on results	Inter-rater reliability (ICC > 0.99 for all domains); responsiveness ($p=0.02-0.005$); ¹² intra-rater reliability: participants unable to repeat test because of fatigue
Barthel Index (BI) ^{100,97}	10 ADLs ^a measured on a 0–2 scale	Dependence: total = 0–4; severe = 5–12; moderate = 6–18; slight = 19; independent = 20	Used to assess patients in the post-ICU period ²⁴
Functional Independent Measure (FIM) ¹¹	18 ADLs in motor and cognitive themes ^b ; 7-point ordinal scales; performed by a multi-disciplinary team over 72-hour period	Score range 18–126 (fully dependent–functional independence)	Acceptable levels of reliability and validity ¹⁴ ; possible ceiling effects, particularly in outpatient settings ⁹⁸
Functional Ambulation Categories (FAC) ⁹⁹	6-point ordinal scale ^c assessing ambulation	Descriptive categories reflect function	Can be used to assess progress in walking in ICU cohort
Glittre ADL Test ¹³	5 laps of a 10-metre walk with steps and carrying, lifting and bending activities ^d	Time-measurement; 4–5 min for in-patient pulmonary rehabilitation; ADL-time associated with disease severity ¹³	Responsive to intervention ¹³ ; used for patients with COPD, but not currently with survivors of a critical illness
<i>Walk tests</i>			
Six Minute Walk Test (6MWT) ¹⁸	Distance walked in six minutes on a 30 m flat track or circuit. Requires the person to walk as far as possible in the six minutes. Standardised encouragement provided each minute. Rests permitted but rest time is included in the six minute period. Heart rate and oxygen saturation should be measured during the test.	The minimum important difference for the 6MWT based on changes following pulmonary rehabilitation has been variously reported as 10% or 35 m (95%CI 30–42) ¹⁰⁰ and 14% or 25 m (95%CI 20–61) ¹⁰¹	Reflects functional capacity in respiratory or cardiac diseases
Incremental Shuttle Walk Test (ISWT) ²⁸	Participants walk round a 10 m track (1 shuttle) in time with audio prompts. Walking speed increases each minute; 12 levels of speed (0.5–2.37 m/s). Number of shuttles and distance walked recorded. Heart rate and oxygen saturation should be measured during the test.	The minimum clinically important improvement in ISWT after pulmonary rehabilitation in COPD is reported as 47.5 m (95% CI 38.6–56.5) ³⁰	Used to assess patients in the post-ICU period ¹⁰²
Timed Up and Go (TUG) ³¹	Stand from sitting in a chair, walk 3 m at regular pace and return to sit in the chair	Normal ≤ 10 s; good mobility, independent ≤ 20 s; requires supervision/walk aid = 21–30 s	Used to assess patients in the post-ICU period ¹⁰²

ICC: intra-class coefficients.

^a Barthel Activities of Daily Living: feeding; moving from wheelchair to bed and return; grooming; toilet transfer; bathing; walking on level surface; propelling a wheelchair; ascending or descending stairs; dressing and undressing; controlling bowels; controlling bladder.

^b FIM themes/items: 13 motor items covering personal care, sphincter control, mobility, locomotion; 5 cognitive items covering communication and social cognition.

^c FAC categories: 0 = unable to walk or requires ≥ 2 people; 1 = continuous firm support from 1 person to walk; 2 = continuous or intermittent support from 1 person; 3 = verbal supervision or stand-by help (without physical contact) from 1 person; 4 = walk independently on level ground; requires help on stairs, slopes, uneven surfaces; 5 = walk independently anywhere.

^d Glittre test: stand from seated position with a back pack (2.5 kg for women; 5.0 kg for men), walk 10 m including interposed two-step staircase to two shelves at shoulder and waist height; move 3×1 kg cartons one by one from the top shelf to the bottom shelf to the floor, then back to the bottom shelf then the top shelf; then walk return over the stairs and sit in the chair and then repeat (5 laps in total).

^e PFIT activities: sit to stand with assistance (number of 0–3 people); marching on spot (MOS) (time, steps and steps/minute (cadence) recorded); bilateral shoulder flexion (through available range) (time, repetitions and cadence); muscle strength testing (Oxford scale 0–5) for knee extension and shoulder flexion.

Table 2 Responsiveness of the PFIT before and after weaning from mechanical ventilation.¹²

Domain	Mean difference before and after weaning	95% CI	P value
<i>Marching on the spot</i>			
Steps	+86.3	15.8–156.8	0.02
Seconds	+56	5.2–102.8	0.03
Cadence	+25.4	–1.7 to 50.3	0.04
<i>Shoulder flexion</i>			
Reps	+8	0.5–25.4	0.02
Seconds	+5.5		
Sit to stand	2 or less people		0.007
Muscle strength	+2 strength grades		0.005

separately. The Functional Status Score for the ICU (FSS-ICU) was further modified after the validity and reliability were assessed. These papers demonstrate that functional tests as they currently exist are not transferrable to ICU populations but that investigators are interested in exploring the clinimetrics of modified or alternative measures.¹⁶

Physical function in ICU test (PFIT)

The PFIT¹² was recently developed in Australia as a sub-maximal exercise test to be both an outcome measure and from which exercise can also be prescribed. It was specifically developed for patients in ICU who were unable to mobilise away from their bedside. The PFIT has four domains that reflect clinically important aspects of physical function that are likely to be responsive to training (Table 1) and was based on interventions that physiotherapists reportedly used during rehabilitation in ICU to assess endurance, muscle strength, exercise capacity and functional ability.¹⁷ Performance of the PFIT involves sitting the patient out of bed in a chair. After a practice of sitting to standing, the test is administered using standardised instructions in the order of tasks presented in Table 1. Exercise training for each domain can be prescribed based on the PFIT results, e.g. marching on the spot 70–80% of the time achieved in the initial PFIT assessment.

The reliability and responsiveness of the PFIT was investigated in a small cohort of ventilated patients ($n = 12$). Responsiveness was assessed prior to and following weaning from mechanical ventilation with a mean time difference of six days between tests. All domains of strength, function and endurance showed improvement (Table 2). Validity testing of the PFIT remains a challenge, as there is no gold standard for measurement of exercise capacity in the critically ill population. Ongoing research involves the development of a total test score for the four domains of the PFIT, determining the predictive ability of the score and correlation

with other functional outcome measures such as the Six Minute Walk Test and the Timed Up and Go test which are described below.

Walk tests

While the walk tests used in rehabilitation practice are commonly performed as sub-maximal tests, in debilitated patients they can act as maximal tests; this may be the case for recovering critically ill patients during initial and early assessment of mobility. The most common and relevant walk tests in this context are the six-minute walk test (6MWT), the Incremental Shuttle Walk Test (ISWT), and the Timed Up and Go (TUG).

Six-minute walk test (6MWT)

The 6MWT is a common measure of functional exercise capacity performed as a self-paced test in which the patient walks as far as possible in six minutes on a flat track. The recommended shuttle track length is 30 m, although track lengths of 20–50 m and circular tracks have been used.¹⁸ It is recommended that two walk tests be performed at each assessment to account for a learning effect.¹⁸ A significant increase in the distance walked in a second test has been demonstrated in chronic obstructive pulmonary disease (COPD),¹⁹ chronic heart failure (CHF)²⁰ and in patients recovering from a critical illness.²¹

Practical guidance for performing the 6MWT is available.²² Standardised encouragement is given each minute by the assessor. A patient can stop and rest, but this time is counted within the six minutes.¹⁸ The ability for a rest makes the 6MWT a useful measure, as the same test can be used across the continuum from critical illness to recovery. However, for patients who reach high levels of physical performance after an ICU admission, stride length and speed may limit the distance walked resulting in a 'ceiling effect'.²³ In contrast, very

disabled patients in ICU or after ICU-discharge may not walk at all resulting in a 'floor effect'. For example, almost 40% of patients were not able to walk or required 2 or more assistants, 4 days after ICU-discharge in a Dutch observational study ($n = 69$).²⁴

The 6MWT has been used to evaluate recovery from a critical illness post-ICU discharge.^{25,26} The most important determinants of walk distance in the 12 months following ICU discharge were identified as the use of systemic corticosteroid treatment during ICU, the presence of illness acquired in ICU, and the rate of resolution of lung injury and multi-organ dysfunction during ICU admission.²⁶

The 6MWT correlated strongly with walking time ($r = 0.76$) and walking intensity ($r = 0.62$) in daily life in patients with COPD²⁷ and moderately with self-reported physical function (PF of the SF-36) in patients recovering from a critical illness ($r = 0.59$).²¹

Incremental shuttle walk test (ISWT)

The ISWT is an externally paced walking test in which the patient walks around two cones placed 9 m apart, giving a total track length of 10 m.²⁸ The initial walking speed is very slow and work rate (i.e. velocity) increases each minute. The test continues until the participant indicates the need to stop or can no longer keep up with the external auditory pacing. The ISWT has been validated in people with COPD.²⁸ Practical guidance on performing the ISWT is available.²² The ICU environment is likely to render the ISWT impractical due to the need for a 10 m track, auditory pacing and turning around cones while attached to equipment. As well, patients need adequate cognitive function to comprehend the test requirements. However, in the immediate post-ICU environment the ISWT could be considered for the assessment of exercise capacity as the test has reflected peak exercise capacity in people with moderate to severe COPD²⁹ and is responsive to change.³⁰

Timed up and go (TUG)

The TUG test was designed as a measure of mobility and gait performance³¹ and was modified from an earlier test, the Get Up and Go Test. The TUG measures how quickly a person can rise from a standardised seated position, walk 3 m, turn around, walk back to the chair and sit down. Performance is measured using a stopwatch, requires little equipment to perform and therefore has high clinical utility. One of the advantages of the TUG test is that normative values exist for comparison (Table 1)³²; completion within 10 s is considered normal

mobility. The time score correlates with a log transformed score of the Barthel Index ($r = -0.78$).³¹

Strength tests

Testing of muscle strength in upper and lower limbs is widely used by clinicians to assess patients with neuromuscular deficits.³³ Muscle strength can be measured quantitatively using dynamometry or as a clinical assessment by manual muscle testing (MMT).³⁴ MMT has been selected as the technique to assess for ICU-AW because of its ease of use and clinical utility.⁸ Dynamometry is also limited in severe muscle weakness when movement cannot be performed against resistance.³⁴

Muscle strength can be assessed either statically (isometric contraction) or through range of movement with and without resistance. Both methods have been reliable and sensitive to change in non-critically ill populations.^{35,36} However the levels of agreement between isometric and through range muscle strength testing has not been clearly established.

Muscle strength testing

Clinical assessment of muscle strength has been commonly described using a six-point ordinal scale (grades 0–5), with variations including the Oxford, Kendall and Medical Research Council (MRC) scales,³⁷ and one using narrative descriptions for levels of muscle contraction (normal, good, fair, poor, and trace or zero).³⁸ While these scales use differing symbols they are essentially based on similar principles: the presence or absence of gravity as a resistance, the arc of movement and the external/manual resistance applied to oppose a movement. Differences between scales include the position of testing, the stabilisation of surrounding structures, the level of resistance applied and the extent of sub-divisions between each strength grade.³³

The MRC scale has been routinely used in critical care research to screen for muscle weakness.^{39–41} This scale classifies muscle contraction as a 0–5 point ordinal scale⁴²: 0 = no muscle contraction; 1 = flicker or trace of muscle contraction; 2 = active movement with gravity eliminated; 3 = reduced power but active movement against gravity; 4 = reduced power but active movement against gravity and resistance; and 5 = normal power against full resistance.⁴³

Assessment of six muscle groups bilaterally for strength and symmetry (upper limb – shoulder abduction, elbow flexion, and wrist extensors; lower limb – hip flexion, knee extension, and ankle dorsiflexion)⁴⁴ has been used for the diagnosis of

ICU-AW. Patients are assessed seven days following awakening; a score of <48/60 (<4 in all testable muscle groups) indicates weakness associated with increased mortality and morbidity. There is however some conflicting evidence regarding the reliability of performing MMT in critically ill patients.⁴⁵ In addition, low rates of patients able to perform MMT while in ICU are reported due to the effects of sedation and the presence of delirium.⁴⁵ Despite these limitations MMT remains the suggested standard tool to diagnose ICU-AW.^{44–46}

Further questions however remain in relation to testing. Unlike other methods of testing and grading muscle strength,^{38,47} the MRC scale does not account for the range of motion through which the movement is performed, or the level of resistance applied. This leads to potential discrepancies in the method of measurement. While some scales advocate 'through range muscle strength assessment', the MRC scale does not clearly state whether muscle tests should be performed through range or as an isometric contraction. Also, while reliability has been established for both methods of strength assessment in non-critically ill populations, there are no data recording levels of agreement for the different approaches. Recent publications regarding the reliability of this form of testing do not describe the actual method of measurement, nor the joint angle at which the measurement of isometric force is made.^{45,46} A consensus on methodology of strength testing is therefore required given that MMT using the MRC scale is currently the preferred screening or diagnostic tool for the presence of ICU-AW.

Hand held dynamometry

Hand held dynamometer (HHD) manual muscle test is a common measurement of strength and has been used in many different patient populations including cancer, COPD and elderly women.^{32,48,49} Maximal contraction of the muscle group to be tested is encouraged while the operator resists the movement by holding the HHD in an appropriate position. The starting position of the person/movement and point of joint range of application are important factors in reproducibility and achieving a valid test. Measurements of shoulder abduction, knee extension and ankle dorsi-flexion have been reported, with responsiveness to change evident over time or post-exercise intervention.³² HHD has demonstrated good intra-rater and inter-rater reliability for the measurement of shoulder strength, quadriceps and ankle dorsi-flexion^{50,51} with trained physiotherapists. Quadriceps strength may be underestimated by HHD if the ability of the tester to resist knee extension is not adequate.

Hand-grip strength is a subset of HHD and enables measurement of force using a calibrated device for patients who are conscious and cooperative. Dynamometry is a reliable, rapid and simple alternative to comprehensive MMT assessment,⁴⁴ and may be a surrogate for global strength.⁸ Normative data are available.^{52–54}

Health-related quality of life (HRQOL)

Quality of life is a broad concept that incorporates all aspects of an individual's existence. Health-related quality of life (HRQOL) is a subset relating to the health domain of that existence, and is now viewed as an important patient-centred health outcome for survivors of a critical illness. Several review papers have identified the commonly used generic HRQOL instruments, and discussed their features and limitations.^{2–5,55,56} These instruments are described here in relation to their assessment of physical function (see Table 3). These self-report HRQOL instruments can be administered in person, by phone or by mail and can be completed by the patient or a proxy (significant other). Proxy completion on behalf of the patient may be necessary in many instances in critical care where the patient is unable to respond (e.g. sedated, agitated, and cognitively impaired). A person most able to replicate the patient perspective is needed to provide substitute judgment about HRQOL.⁵⁷ The use of proxies appears sensible, as the critical illness itself may influence a patient's recollection of their pre-admission health status. Use of proxies may however not accurately estimate HRQOL, with several conflicting reports regarding proxy estimations published.^{58–61}

Retrospective completion of pre-illness/baseline HRQOL information is often necessary in the critical care setting,⁶² with pre-morbid HRQOL an important determinant of HRQOL after ICU.^{3,63} Apart from proxy completion, this is commonly the only method to obtain these data. The baseline response and further completion of HRQOL instruments after ICU discharge can be affected by recall bias and response shift⁶⁴; the latter is when patients change their value and perceptions of HRQOL after their illness.⁶⁴ Response shift measurement has not been undertaken with critical care patients to date.⁶⁵ These measurement issues related to HRQOL therefore need to be considered when reading and interpreting data in this area of critical care practice.

Some instruments are also multi-attribute utility instruments (MAU); e.g. AQoL, EuroQol 5D. Utility measures are based on patient preferences for a particular health state, and provide a single

Table 3 Summary of generic HRQOL instruments used for patients following a critical illness (adapted from¹⁰³).

Instrument	Items; domains/concepts examined
Medical outcomes study (SF-36) ^{74,104}	36 items in 8 domains; physical: functioning, role limitations, pain, general health; mental: vitality, social, role limitations, mental health; health transition; variable response levels (2–5); Mental and Physical Component Summary calculated from domains
Assessment of quality of life (AQoL) ⁶⁷	15 items in 5 domains: illness (3 items); independent living (3 items); physical senses (3 items); social relationships (3 items); psychological well-being (3 items); 4 response levels; measured on a scale from 0.04 (state worse than death) to 1.00 (full health) where 0.0 is death equivalent; enables cost-utility analysis
15D ^{92,105}	15 items/domains: mobility, vision, hearing, breathing, sleeping, eating, speech, elimination, usual activities, mental function, discomfort, distress, depression, vitality, and sexual activity; 5-point ordinal scale (1 = full function; 5 = minimal/no function)
EuroQol 5D ^{68,92,106}	Adapted from 15D; 5 items: mobility, self-care, usual activities, pain/discomfort, anxiety/depression; 3 response levels; cost-utility index calculated
Nottingham Health Profile (NHP) ⁶⁹	45 items; experience: energy, pain, emotional reactions, sleep, social isolation, physical mobility; daily life: employment, household work, relationships, home life, sex, hobbies, and holidays
Quality of life – Italian (QOL – IT) ⁷⁰	5 items: physical activity; social life; perceived quality of life; oral communication; functional limitation; varied response levels (4–7)
Quality of life – Spanish (QOL – SP) ⁷¹	15 items: basic physiological activities (4 items); normal daily activities (8 items); emotional state (3 items)
Perceived quality of life (PQOL) ⁷²	11 items on satisfaction with: bodily health; ability to think/remember; happiness; contact with family and friends; contribution to the community; activities outside work; whether income meets needs; respect from others; meaning and purpose of life; working/not working/retirement; each scored on 0–100 scale
Sickness impact profile (SIP) ^{73,107}	68 item short-version/136 items in 6 domains; physical: body movement, mobility, ambulation; psychosocial: intellectual, social interaction, emotional behaviour, communication; sleep and rest; daily work; household; leisure and recreation

summary score of outcome. Utility measures are particularly important when there are both mortality and morbidity effects and some integration of them is required, as may be the case in ICU. The conventional scale in which the state of being dead (the lack of health status) is assigned a score of 0.00 and perfect health is assigned a score of 1.00 provides a framework for the integration of mortality and morbidity. Utility scores are useful as measures of outcome and as 'inputs' in economic evaluations.⁶⁶

The most common instrument used to measure HRQOL is the Short-Form 36 (SF-36); of 53 studies reviewed, 55% used SF-36⁴ – see below. Also described is the AQoL, an Australian developed instrument,⁶⁷ and the EuroQol (EQ-5D),⁶⁸ used in 21% of studies in the above review.⁴ Other instruments listed in Table 3 are mostly used in specific countries,^{69–71} or are older and now less favoured in relation to more recently developed instruments.^{72,73}

Short-form general health survey (SF-36)

The Medical Outcomes Study 36-item SF-36 health survey is a commonly used and well-validated instrument in many different disease populations.⁷⁴ The 36-item instrument has been widely used^{26,59,75–80} and recommended in critical illness.^{5,81} Benefits of using SF-36 include published national and international normative data,^{74,82–85} and the minimal important difference (MID) transformed domain scores are reported to be ≥ 5 points^{3,74} but range as high as 10–25 points in SF-36 Version 2.⁸⁶ Reporting using norm based scores is recommended, where mean \pm SD is 50 ± 10 for each domain. The MID for SF-36 norm based scores has been reported to be 2 points for domain scores < 40 and 3 points for domain scores > 40 .⁷⁴ The SF-36 has demonstrated reliability, validity and responsiveness,⁸⁷ in critical illness populations.

A further feature is that a utility measure can be derived from the SF-36, using 11 of the items from seven domains, called the SF6D. This version

has not however yet been validated in the critical illness population. One limitation in this setting is that SF-36 cannot account for a patient who is deceased, and missing data therefore becomes an issue in analysis and bias may be increased.

Assessment of quality of life (AQoL)

The AQoL is a generic MAU instrument designed to evaluate the cost-effectiveness of healthcare intervention by directly calculating utility scores.⁶⁷ As a HRQoL, the AQoL also allows measurement of health domains similar to the SF-36 (Table 3), and is validated in different patient groups^{88,89} but not in the critical care setting to date. Utility scores range from 1.00 (best QoL state) to -0.04 (worst QoL state) where 0.00 is a death-equivalent state. Normative Australian AQoL data are available, and the MID for the AQoL is 0.06 points.⁹⁰ A newly developed shortened version is also now available – The AQoL 8,⁹¹ although use in ICU populations has not yet been reported.

EuroQol 5D

The EuroQol 5D (EQ-5D)^{68,106} was developed from the 15D Health Survey¹⁰⁵ (Table 3), and similar to the AQoL is both a HRQoL and an MAU instrument. While a more brief instrument, a recent comparison demonstrated that the longer 15D instrument was more sensitive to clinically important differences in health status than EQ-5D for survivors of a critical illness.⁹² A previous study had demonstrated more sensitivity with SF-36 than 15D during recovery after cardiac surgery⁹³ and critical illness.⁵⁹

Economic evaluation

The use of MAU instruments enables an economic evaluation to be conducted; measuring the cost effectiveness of an intervention is now an important consideration in health care decision-making globally. Increasing cost pressures are due to advances in medical technology leading to increased demand for services; the aging population and population growth generally.⁹⁴ The basic premise of health care economic evaluation is that resources available for health care are limited, so choices have to be made regarding which services are funded. Within this framework, there are three key concepts underlying economic evaluation: It defines inputs and outputs, described as *costs and consequence*; making choices between options; and comparing programs using transparent criteria.

Economic evaluations are usually undertaken from one of three perspectives⁹⁵: (1) the health service perspective is where only the costs of providing a health service are considered. (2) The patient per-

spective includes both health service and patient costs; and (3) the societal perspective includes all costs (e.g. a cost utility or cost-benefit analysis). This last perspective is recommended⁹⁶ as it is the most comprehensive. In this analysis the patient outcome is measured using a MAU. The utility value (0–1) can be used to calculate quality adjusted life years (QALYs), an outcome measure that accounts for both the quantity and the quality of the extra life provided by the healthcare intervention being investigated. The utility value of a health state is multiplied by the length of time spent in that health state – one year of perfect health (utility value of 1) equals one QALY. For example if a person went from a HRQoL state of 0.5 to 1.0, and maintained this for 2 years, the QALY gain would be 1.00 (0.50 × 2.00).

One of the most useful aspects of QALYs is that they allow the ‘value for money’ provided by different interventions to be measured in a common unit – ‘cost per QALY’. This can provide information on the comparative effectiveness of interventions within the same disease area and the relative effectiveness of interventions from different therapy areas. Ideally, cost effective programs indicate that there is a good probability of generating a QALY for a relatively low cost.

Most health care professionals undertaking research now include some type of economic measure of an intervention program. However, economic evaluations can be complex and require high levels of data collection. A Health Economist is recommended to guide this process and assist with analysis and interpretation of results.

Discussion

This review has highlighted a number of practice issues requiring consideration as we collectively aim to improve the recovery for survivors of a critical illness. Despite potential reliability and methodological issues, the assessment of muscle strength using the MRC scale in ICU remains the diagnostic technique of choice to screen for the presence of ICU-AW. While consensus panels have been developing definitions and guidelines for the clinical diagnosis of ICU-AW,⁴¹ related fundamental assessment issues on the standardised procedure for manual muscle testing with the MRC scale has had little evaluation.

There are currently also many different functional outcomes used in ICU research. As yet we have not confirmed which are the most valid and sensitive to use in different ICU populations. It is probable that some tests have ceiling effects (e.g.

FIM) and others will have floor effects early in recovery for this heterogeneous population (e.g. 6MWT). While SF-36 remains the most commonly used instrument for assessing HRQOL in a variety of critically ill patient groups, further work continues in establishing the most appropriate instrument for use in critical care cohorts.

Some limitations of this narrative review are noted. While this review has focused on physical assessment, it is clear that a holistic approach is required that also addresses psychological and cognitive components of recovery. Other functional instruments with similar domains to the BI or FIM have been used with ICU patients in some studies, but not commonly, and were therefore not included here. Similarly, only common generic HRQOL instruments were reviewed; disease-specific instruments were excluded because of their lack of utility to general ICU patients.

Implications for practice

The assessment of physical function in ICU survivors is multidimensional and involves establishing pre-morbid function, screening for the presence of ICU-AW and monitoring recovery of strength and function in the context of HRQOL. Critical care nurses and ICU liaison nurses should routinely assess strength, functional ability and mobility for their patients to identify those at risk of delayed recovery. In patients who have a prolonged ICU stay complicated by sepsis, ICU-AW should be suspected and an MRC score of muscle strength recorded. For patients with an MRC score of <48, a rehabilitation programme should commence while the patient is in ICU, with recovery monitored using outcomes such as the PFIT and field walking tests. ICU follow-up services should also consider routine assessment of HRQOL for identified patients at risk of delayed and sub-optimal recovery.

Improved education of the wider health care community (e.g. General Practitioners; Community Nurses) about the ongoing legacy of a critical illness, that includes monitoring and responses to weakness and loss of functional capacity, should be implemented.

Recommendations for further research

This review has provided information on instruments available for measuring physical function and activity in survivors of a critical illness. To appropriately assess weakness and poor physical function in survivors of a critical illness and to measure responses to interventions aimed at improving physical function, further validation of some of these

instruments and development of new instruments is required. As noted earlier, consensus around the methodology for muscle testing needs to be developed.

Concurrently, assessment and treatment strategies that are safe, feasible and cost effective need to be identified that reduce the risks of developing ICU-AW including changes of culture to less sedation and immobility to more patient activity and targeted rehabilitation programs. Importantly, a 'package' of interventions needs to be developed that target both cognitive and functional outcomes and these need to be tested using rigorous collaborative research in ICU populations, to inform and enable national and international comparisons.

Conclusions

This narrative review described assessment of physical function and recovery during the continuum of critical illness – from in-ICU to the post-ICU hospital and hospital discharge periods. Physical debilitation from a patient's critical illness and treatment may result in a decline in functional capacity, which affects the recovery trajectory for survivors of a critical illness. Assessment of physical function involves clinical assessment of muscle strength, physical activity, mobility and functional ability. The common techniques and instruments were discussed, with limitations or challenges in practice noted. Standardisation in assessment practices and resulting rehabilitation and recovery plans requires consistent engagement from multidisciplinary teams in critical care, but also from physical and medical rehabilitation specialities.

References

1. Williams TA, Dobb GJ, Finn JC, Knuiman MW, Geelhoed E, Lee KY, et al. Determinants of long-term survival after intensive care. *Crit Care Med* 2008;**36**:1523–30.
2. Adamson H, Elliott D. Quality of life after a critical illness: a review of general ICU studies 1998–2003. *Aust Crit Care* 2005;**18**:50–60.
3. Dowdy DW, Eid MP, Sedrakyan A, Mendez-Tellez PA, Pronovost PJ, Herridge MS, et al. Quality of life in adult survivors of critical illness: a systematic review of the literature. *Intensive Care Med* 2005;**31**(5):611–20.
4. Oeyen SG, Vandijck DM, Benoit DD, Annemans L, Decruyenaere JM. Quality of life after intensive care: a systematic review of the literature. *Crit Care Med* 2010;**38**(12):2386–400.
5. Angus DC, Carlet J. Surviving intensive care: a report from the 2002 Brussels Roundtable. *Intensive Care Med* 2003;**29**(3):368–77.
6. Stevens RD, Dowdy DW, Michaels RK, Mendez-Tellez PA, Pronovost PJ, Needham DM. Neuromuscular dysfunction

- acquired in critical illness: a systematic review. *Intensive Care Med* 2007;**33**(11):1876–91.
7. Griffiths RD, Hall JB. Intensive care unit-acquired weakness. *Crit Care Med* 2010;**38**(3):779–87.
 8. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, de Jonghe B, et al. A framework for diagnosing and classifying intensive care unit-acquired weakness. *Crit Care Med* 2009;**27**(10 Suppl.):S299–308.
 9. Vasilevskis EE, Ely EW, Speroff T, Pun BT, Boehm L, Dittus RS. Reducing iatrogenic risks: ICU-acquired delirium and weakness—crossing the quality chasm. *Chest* 2010;**138**(5):1224–33.
 10. Wade DT, Collin C. The Bathel ADL Index: a standard measure of physical disability? *Disability Rehabilitation* 1988;**10**(2):64–7.
 11. Uniform Data Set for Medical Rehabilitation. *The clinical guide for the uniform data set for medical rehabilitation (including the FIM™ Instrument)*. Buffalo, NY: State University of New York at Buffalo; 2009 [cited 11.01.11]; Available from: <http://www.udsmr.org/WebModules/FIM/Fim.About.aspx>.
 12. Skinner EH, Berney S, Warrillow S, Denehy L. Development of a physical function outcome measure (PFIT) and a pilot exercise training protocol for use in intensive care. *Crit Care Resusc* 2009;**11**(June (2)).
 13. Skumlien S, Hagelund T, Bjørtuft Ø, Ryg MS. A field test of functional status as performance of activities of daily living in COPD patients. *Respir Med* 2006;**100**(2):316–23.
 14. Cohen ME, Marino RJ. The tools of disability outcomes research functional status measures. *Arch Phys Med Rehabil* 2000;**81**(12 (Suppl. 2)):S21–9.
 15. Dennis DM, Hebden-Todd TK, Marsh LJ, Cipriano LJ, Parsons RW. How do Australian ICU survivors fare functionally 6 months after admission? *Crit Care Resusc* 2011;**13**(1):9–16.
 16. Zanni JM, Korupolu R, Fan E, Pradhan P, Janjua K, Palmer JB, et al. Rehabilitation therapy and outcomes in acute respiratory failure: an observational pilot project. *J Crit Care* 2009.
 17. Skinner EH, Berney S, Warrillow S, Denehy L. Rehabilitation and exercise prescription in Australian intensive care units. *Physiotherapy* 2008;**94**(3):220–9.
 18. American Thoracic Society. Guidelines for the six-minute walk test. *Am J Resp Crit Care Med* 2002;**166**:111–7.
 19. Sciruba F, Criner GJ, Lee SM, Mohsenifar Z, Shade D, Slivka W, et al. Six-minute walk distance in chronic obstructive pulmonary disease: reproducibility and effect of walking course layout and length. *Am J Respir Crit Care Med* 2003;**167**(11):1522–77.
 20. Opasich C, Pinna GD, Mazza A, Febo O, Riccardi R, Riccardi PG, et al. Six-minute walking performance in patients with moderate-to-severe heart failure: is it a useful indicator in clinical practice? *Eur Heart J* 2001;**22**(6):488–96.
 21. Alison JA, Elliott D, McKinley S, Aitken LM, King MT, Leslie GD, et al. Repeatability of six-minute walk test and relation to physical function in survivors of a critical illness. *Aust J Physiother [serial on the Internet]* 2009;**55**(4 (eSupplement)). Available from: <http://www.physiotherapy.asn.au/index.php/quality-practice/ajp/esupplements>.
 22. Alison J, Barrack C, Cafarella P, Frith P, Hanna C, Hill C, et al. The Pulmonary Rehabilitation Toolkit; 2009 [cited 11.01.11]. Available from: <http://www.pulmonaryrehab.com.au/welcome.asp>.
 23. Frost AE, Langleben D, Oudiz R, Hill N, Horn E, McLaughlin V, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. *Vascul Pharmacol* 2005;**43**(1):36–9.
 24. van der Schaaf M, Dettling DS, Beelen A, Lucas C, Dongelmans DA, Nollet F. Poor functional status immediately after discharge from an intensive care unit. *Disability Rehabil* 2008;**30**(23):1812–8.
 25. Elliott D, McKinley S, Alison JA, Aitken LM, King MT, Leslie GD, et al. Outcomes for survivors of a critical illness: effects of home-based physical rehabilitation. In: *34th Australian and New Zealand annual scientific meeting on intensive care*. 2009.
 26. Herridge MS, Cheung AM, Tansey CM, Matte-Marmtyn A, Diaz-Granados N, Al-Saidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. *N Eng J Med* 2003;**348**(8):683–93.
 27. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 2005;**171**:972–7.
 28. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients with chronic airways obstruction. *Thorax* 1992;**47**(12):1019–24.
 29. Luxton N, Alison JA, Wu J, Mackey MG. Relationship between field walking tests and incremental cycle ergometry in COPD. *Respirology* 2008;**13**:856–62.
 30. Singh SJ, Jones PW, Evans R, Morgan MDL. Minimum clinically important improvement for the incremental shuttle walking test. *Thorax* 2008;**63**:775–7.
 31. Podsiadlo D, Richardson S. The Timed Up and Go: a test of basic functional mobility for frail elderly persons. *J Am Geriatric Soc* 1991;**39**(2):142–8.
 32. Bohannon RW. Reference values for the timed up and go test: a descriptive meta-analysis. *J Geriatric Phys Therapy* 2006;**26**:64–8.
 33. Florence JM, Pandya S, King WM, Robison JD, Baty J, Miller JP, et al. Intrarater reliability of manual muscle test (Medical Research Council scale) grades in Duchenne's Muscular Dystrophy. *Phys Therapy* 1992;**72**:115–26.
 34. Paternostro-Sluga T, Grim-Stieger M, Posch M, Schuhfried O, Vacariu G, Mittermaier C, et al. Reliability and validity of the medical research council scale and a modified scale for testing muscle strength in patients with radial palsy. *J Rehabil Med* 2008;**40**:665–71.
 35. Great Lakes ALS study group. A comparison of muscle strength testing techniques in amyotrophic lateral sclerosis. *Neurology* 2003;**61**:1503.
 36. Kean CO, Birmingham TB, Garland SJ, Bryant BM, Griffin JR. Minimal detectable change in quadriceps strength and voluntary muscle activation in patients with knee osteoarthritis. *Arch Phys Med* 2010;**91**:1447–51.
 37. Fosang A, Baker R. A method for comparing manual muscle strength measurements with joint moments during walking. *Gait Posture* 2006;**24**:406–11.
 38. Daniels L, Worthingham C. *Muscle testing: technique of manual examination*. Philadelphia: WB Saunders Co.; 1986.
 39. De Jonghe B, Sharshar T, Lefaucheur J, Authier F, Durand-Zaleski I, Boussarsar M, et al. Paresis acquired in the intensive care unit: a prospective multicenter study. *JAMA* 2002;**288**(22):2859–66.
 40. De Jonghe B, Lacherade J-C, Durand M-C, Sharshar T. Critical illness neuromuscular syndromes. *Crit Care Clinics* 2007;**23**(1):55–69.
 41. Stevens RD, Marshall SA, Cornblath DR, Hoke A, Needham DM, deJonghe B, et al. A framework for diagnosing and

- classifying intensive care unit-acquired weakness. *Crit Care Med* 2009;**37**:S299–308.
42. United Kingdom Medical Research Council. *Aids to the examination of the peripheral nervous system*. Edinburgh: W.B. Saunders; 2000.
 43. Brain. *Aids to the examination of the peripheral nervous system*. Edinburgh: W.B. Saunders Co.; 2000.
 44. Ali NA, O'Brien JM, Hoffmann SP, Phillips G, Garland A, Finley JCW, et al. Acquired weakness, handgrip strength, and mortality in critically ill patients. *Am J Resp Crit Care Med* 2008;**178**(3):261.
 45. Hough CL, Lieu BK, Caldwell ES. Manual muscle strength testing of critically ill patients: feasibility and interobserver agreement. *Crit Care* 2011;**15**:R43.
 46. Fan E, Ciesla ND, Truong AD, Bhoopathi V, Zeger SL, Needham DM. Inter-rater reliability of manual muscle strength testing in ICU survivors and simulated patients. *Intensive Care Med* 2010;**36**(6):1038–43.
 47. Kendall F, McCreary E. *Muscle testing and function*. Baltimore: Williams and Wilkins; 1983.
 48. Knols RH, Aufdemkampe G, de Bruin ED, Uebelhart D, Aaronson NK. Hand-held dynamometry in patients with haematological malignancies: measurement error in the clinical assessment of knee extension strength. *BMC Musculoskelet Disord* 2009;**9**(10):31.
 49. O'Shea SD, Taylor NF, Paratz JD. A predominantly home-based progressive resistance exercise program increases knee extensor strength in the short-term in people with chronic obstructive pulmonary disease: a randomised controlled trial. *Aust J Physiother* 2007;**53**(4):229–37.
 50. Hayes K, Callanan M, Walton J, Paxinos A, Murrell GA. Shoulder instability: management and rehabilitation. *J Orthop Sports Phys Ther* 2002;**32**(10):497–509.
 51. O'Shea SD, Taylor NF, Paratz JD. Measuring muscle strength for people with chronic obstructive pulmonary disease: retest reliability of hand-held dynamometry. *Arch Phys Med Rehabil* 2007;**88**(1):32–6.
 52. Mathiowetz V, Kashman N, Volland G, Weber K, Dowe M, Rogers S. Grip and pinch strength: normative data for adults. *Arch Phys Med Rehabil* 1985;**66**(2):69–74.
 53. Mroszczyk-McDonald A, Savage PD, Ades PA. Handgrip strength in cardiac rehabilitation: normative values, interaction with physical function, and response training. *J Cardiopulmonary Rehabil Prevent* 2007;**27**(5):298–302.
 54. Puh U. Age-related and sex-related differences in hand and pinch grip strength in adults. *Int J Rehabil Res* 2010;**33**(1):4–11.
 55. Elliott D. Measuring the health outcomes of general ICU patients: a systematic review of methods and findings. *Aust Crit Care* 1999;**12**(December (4)):132–40.
 56. Chaboyer W, Elliott D. Health-related quality of life of ICU survivors: review of the literature. *Intensive Crit Care Nurs* 2000;**16**(April (2)):88–97.
 57. Pickard AS, Knight SJ. Proxy evaluation of health-related quality of life: a conceptual framework for understanding multiple proxy perspectives. *Med Care* 2005;**43**:493–9.
 58. Elliott D, Lazarus R, Leeder SR. Proxy respondents reliably assessed the quality of life of elective cardiac surgery patients. *J Clin Epidemiol* 2006;**59**(2):153–9.
 59. Elliott D, Mudaliar Y, Kim C. Examining discharge outcomes and health status of critically ill patients: some practical considerations. *Intensive Crit Care Nurs* 2004;**20**:366–77.
 60. Scales DC, Tansey CM, Matte A, Herridge MS. Difference in reported pre-morbid health-related quality of life between ARDS survivors and their substitute decision makers. *Intensive Care Med* 2006;**32**(11):1826–31.
 61. Gifford JM, Husain N, Dinglas VD, Colantuoni E, Needham DM. Baseline quality of life before intensive care: a comparison of patient versus proxy respondents. *Crit Care Med* 2010;**38**(3):855–60.
 62. Hofhuis JGM, Spronk PE, van Stel HF, Schrijvers AJ, Bakker J. Quality of life before intensive care unit admission is a predictor of survival. *Crit Care* 2007;**11**(4):R78.
 63. Orwelius L, Nordlund A, Edéll-Gustafsson U, Simonsson E, Nordlund P, Kristenson M, et al. Role of preexisting disease in patients' perceptions of health-related quality of life after intensive care. *Crit Care Med* 2005;**33**(7):1557–64.
 64. Hofhuis JG, van Stel HF, Schrijvers AJ, Rommes JH, Bakker J, Spronk PE. Conceptual issues specifically related to health-related quality of life in critically ill patients. *Crit Care* 2009;**13**(1):118.
 65. Hofhuis JGM, van Stel HF, Schrijvers AJP, Rommes JH, Bakker J, Spronk PE. Health-related quality of life in critically ill patients: how to score and what is the clinical impact? *Curr Opin Crit Care* 2009 Oct;**15**(5):425–30.
 66. Feeny D. A utility approach to the assessment of health-related quality of life. *Med Care* 2000;**38**(9 (Suppl. II)):151–4.
 67. Hawthorne G, Richardson J, Osborne R. The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of health-related quality of life. *Qual Life Res* 1999;**8**(3):209–24.
 68. EuroQol Group. EuroQol: a new facility for the measurement of health-related quality of life. *Health Policy* 1990;**16**(3):199–208.
 69. Hunt S, McKenna S, McEwan J, Backett E, Williams J, Papp E. Measuring health status: a new tool for clinicians and epidemiologists. *J Royal College Gen Pract* 1985;**35**:185–8.
 70. Capuzzo M, Grasselli C, Carrer S, Gritti G, Alvisi R. Validation of two quality of life questionnaires suitable for intensive care patients [comment]. *Intensive Care Med* 2000;**26**(9):1296–303.
 71. Rivera-Fernandez R, Sanchez Cruz SJ, Vazquez Mata G. Validation of a quality of life questionnaire for critically ill patients. *Intensive Care Med* 1996;**22**:1034–42.
 72. Patrick DL, Danis M, Southerland LI, Hong G. Quality of life following intensive care. *J Gen Intern Med* 1988;**3**:218–23.
 73. Bergner M, Bobbitt RA, Carter WB, Gilson BS. The sickness impact profile: development and final revision of a health status measure. *Med Care* 1981;**19**:787–805.
 74. Ware JE, Snow KK, Kosinski M. *SF-36 Version 2 health survey: manual and interpretation guide*. Lincoln: Quality Metric Incorporated; 2000.
 75. Chaboyer W, Foster M, Creamer J. Health status of ICU survivors: a pilot study. *Aust Crit Care* 2002;**15**(1):21–6.
 76. Cuthbertson BH, Rattray J, Campbell MK, Gager M, Roughton S, Smith A, et al. The PRaCTiCal study of nurse led, intensive care follow-up programmes for improving long term outcomes from critical illness: a pragmatic randomised controlled trial. *Br Med J* 2009;**339**:b3723.
 77. Cuthbertson BH, Roughton S, Jenkinson D, MacLennan G, Vale L. Quality of life in the five years after intensive care: a cohort study. *Crit Care* 2010;**14**(R6):1–12.
 78. Cuthbertson BH, Scott J, Strachan M, Kilonzo M, Vale L. Quality of life before and after intensive care. *Anaesthesia* 2005;**60**:332–9.
 79. Hofhuis JG, Spronk PE, van Stel HF, Schrijvers GJ, Rommes JH, Bakker J. The impact of critical illness on perceived health-related quality of life during ICU treatment, hospital stay, and after hospital discharge: a long-term follow-up study. *Chest* 2008;**13**(2):377–85.

80. van der Schaaf M, Beelen A, Dongelmans DA, Vroom MB, Nollet F. Poor functional recovery after a critical illness: a longitudinal study. *J Rehabil Med* 2009 Nov;41(13):1041–8.
81. Black NA, Jenkinson C, Hayes JA, Young D, Vella K, Rowan KM, et al. Review of outcome measures used in adult critical care. *Crit Care Med* 2001;9(November (11)): 2119–24.
82. Australian Bureau of Statistics. *National Health Survey: SF36 Population Norms, Australia, 1995*. Canberra: Australian Bureau of Statistics; 1997.
83. Hawthorne G, Osborne RH, Taylor A, Sansoni J. The SF36 Version 2: critical analyses of population weights, scoring algorithms and population norms. *Qual Life Res* 2007;16(4):661–73.
84. Jenkinson C, Stewart-Brown S, Petersen S, Paice C. Assessment of the SF-36 version 2 in the United Kingdom. *J Epidemiol Community Health* 1999 Jan;53(1):46–50.
85. Scott KM, Tobias MI, Sarfati D, Haslett SJ. SF-36 health survey reliability, validity and norms for New Zealand. *Aust NZ J Pub Health* 1999;23(4):410–6.
86. Wyrwich KW, Tierney WM, Babu AN, Kroenke K, Wolinsky FD. A comparison of clinically important differences in health-related quality of life for patients with chronic lung disease, asthma, or heart disease. *Health Services Res* 2005;40:577–91.
87. Chrispin PS, Scotton H, Rogers J, Lloyd D, Ridley SA. Short form 36 in the intensive care unit: assessment of acceptability, reliability and validity of the questionnaire. *Anaesthesia* 1997;52(1):15–23.
88. Osborne RH, Hawthorne G, Lew EA, Gray LC. Quality of life assessment in the community-dwelling elderly validation of the Assessment of Quality of Life (AQoL) instrument and comparison with the SF-36. *J Clin Epidemiol* 2003;56(2):138–47.
89. Whitfield K, Buchbinder R, Segal L, Osborne RH. Parsimonious and efficient assessment of health-related quality of life in osteoarthritis research: validation of the Assessment of Quality of Life (AQoL) instrument. *Health Qual Life Outcomes* 2006;23(4):19.
90. Hawthorne G, Osborne R. Population norms and meaningful differences for the Assessment of Quality of Life (AQoL) measure. *Aust NZ J Pub Health* 2005;29(2):136–42.
91. Hawthorne G. Assessing utility where short measures are required: development of the short Assessment of Quality of Life-8 (AQoL-8) instrument. *Value Health* 2009;12(6):948–57.
92. Vainiola T, Pettila V, Roine RP, Rasanen P, Rissanen AM, Sintonen H. Comparison of two utility instruments, the EQ-5D and the 15D, in the critical care setting. *Intensive Care Med* 2010;36:2090–3.
93. Elliott D, Lazarus R, Leeder SR. Health outcomes of patients undergoing cardiac surgery: repeated measures using Short Form-36 and 15 Dimensions of Quality of Life questionnaire. *Heart Lung* 2006;35(4):245–51.
94. Wills PJ. The Virtuous Cycle. Working together for health and medical research. Health and Medical Research Strategic Review Summary: Commonwealth of Australia, 1998. In: AsHtsbhrotAloHa, editor. *Welfare*. Canberra: Australian Institute for Health and Welfare; 2000.
95. Drummond MF. Health economic models: a question of balance—summary of an open discussion on the pharmacoeconomic evaluation of non-steroidal anti-inflammatory drugs. *Rheumatology (Oxford)* 2000;39(Suppl. 2):29–32.
96. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. *JAMA* 1996;276(October (15)):1253–8.
97. Novak S, Johnson J, Greenwood R. Barthel revisited: making guidelines work. *Clin Rehabil* 1996;10(2):128–34.
98. Mackintosh S. Functional independence measure [appraisal]. *Aust J Physiother* 2009;55:65.
99. Holden MK, Gill KM, Magliozzi MR, Nathan J, Piehl-Baker L. Clinical gait assessment in the neurologically impaired: reliability and meaningfulness. *Phys Therapy* 1984;64(1):35–40.
100. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schunemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. *Eur Respir J* 2008;32(3):637.
101. Holland AE, Hill CJ, Conron M, Munro P, McDonald CF. Small changes in six-minute walk distance are important in diffuse parenchymal lung disease. *Respir Med* 2009;103(10):1430–5.
102. Salisbury LG, Merriweather JL, Walsh TS. The development and feasibility of a ward-based physiotherapy and nutritional rehabilitation package for people experiencing critical illness. *Clin Rehabil* 2010;24:489–500.
103. Adamson H, Elliott D. Clinical information. In: Elliott D, Aitken LM, Chaboyer W, editors. *ACCCN's critical care nursing*. Sydney: Mosby; 2007. p. 44.
104. Ware JE. SF-36 health survey update. *Spine* 2000;25(December (24)):3130–9.
105. Sintonen H. The 15D instrument of health-related quality of life: properties and applications. *Anna Med* 2001;33:328–36.
106. Brooks R. EuroQol: the current state of play. *Health Policy* 1996;37:53–72.
107. de Bruin AF, Diederikis JP, de Witte LP, Stevens FC, Philipsen H. The development of a short generic version of the sickness impact profile. *J Clin Epidemiol* 1994;47:407–18.

Available online at www.sciencedirect.com



ScienceDirect